Embecta Corp (EMBC)vsJohnson & Johnson (JNJ)
EMBC
Embecta Corp
$5.29
+1.93%
HEALTHCARE · Cap: $279.90M
JNJ
Johnson & Johnson
$269.99
-0.09%
HEALTHCARE · Cap: $640.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 9513% more annual revenue ($97.93B vs $1.02B). JNJ leads profitability with a 21.5% profit margin vs 8.6%. EMBC trades at a lower P/E of 3.4x. JNJ earns a higher WallStSmart Score of 59/100 (C).
EMBC
Hold43
out of 100
Grade: D
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-41.7%
Fair Value
$7.10
Current Price
$5.29
$1.81 premium
Intrinsic value data unavailable for JNJ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Strong operational efficiency at 23.7%
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 8.1%
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : EMBC
The strongest argument for EMBC centers on P/E Ratio, Debt/Equity, Operating Margin.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bear Case : EMBC
The primary concerns for EMBC are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
EMBC profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
EMBC carries more volatility with a beta of 0.85 — expect wider price swings.
JNJ is growing revenue faster at 6.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 43/100), backed by strong 21.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Embecta Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Embecta Corp (EMBC) is a leading medical technology company specializing in innovative insulin delivery systems aimed at enhancing diabetes management. Born from a spin-off of Becton, Dickinson and Company, Embecta provides a comprehensive portfolio of advanced products, including cutting-edge insulin pens and syringes tailored to improve patient outcomes. With a robust focus on operational excellence and customer satisfaction, Embecta is well-positioned to capitalize on growth opportunities in the rapidly expanding diabetes care market, strengthening its leadership in this vital sector.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?